Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Paredes

Showing results (211-220 of 309) with videos related to

Pageof 31
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 1, 2014
Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testingChristian Pou, Marc Noguera-Julian, Susana Pérez-Álvarez, et al.
JAMA|April 7, 2011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
Antiviral Therapy|June 20, 2017
The association between detected drug resistance mutations and CD4<sup>+</sup> T-cell decline in HIV-positive individuals maintained on a failing treatment regimenAnna Schultze, Roger Paredes, Caroline Sabin, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Medicine|October 18, 2016
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort studyJosep M Llibre, Alessandro Cozzi-Lepri, Court Pedersen, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialAnthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, et al.
The Journal of Antimicrobial Chemotherapy|April 24, 2024
Cardiometabolic health in people with HIV: expert consensus reviewRachel L Batterham, Roger J Bedimo, Ricardo S Diaz, et al.
BMC Infectious Diseases|November 14, 2013
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohortIstván Bartha, Matthias Assel, Peter M A Sloot, et al.
Frontiers in Immunology|May 27, 2022
Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-SeroconvertorsAthina Kilpeläinen, Esther Jimenez-Moyano, Oscar Blanch-Lombarte, et al.
AIDS Research and Human Retroviruses|December 31, 2021
A Summary of the Sixth International Workshop on Microbiome in HIV Pathogenesis, Prevention, and TreatmentScott Sherrill-Mix, Michelle Yang, Grace M Aldrovandi, et al.
Pageof 31

Showing results (211-220 of 309) with videos related to

Sort By:
Pageof 31
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 1, 2014
Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testingChristian Pou, Marc Noguera-Julian, Susana Pérez-Álvarez, et al.
JAMA|April 7, 2011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
Antiviral Therapy|June 20, 2017
The association between detected drug resistance mutations and CD4<sup>+</sup> T-cell decline in HIV-positive individuals maintained on a failing treatment regimenAnna Schultze, Roger Paredes, Caroline Sabin, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Medicine|October 18, 2016
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort studyJosep M Llibre, Alessandro Cozzi-Lepri, Court Pedersen, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialAnthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, et al.
The Journal of Antimicrobial Chemotherapy|April 24, 2024
Cardiometabolic health in people with HIV: expert consensus reviewRachel L Batterham, Roger J Bedimo, Ricardo S Diaz, et al.
BMC Infectious Diseases|November 14, 2013
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohortIstván Bartha, Matthias Assel, Peter M A Sloot, et al.
Frontiers in Immunology|May 27, 2022
Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-SeroconvertorsAthina Kilpeläinen, Esther Jimenez-Moyano, Oscar Blanch-Lombarte, et al.
AIDS Research and Human Retroviruses|December 31, 2021
A Summary of the Sixth International Workshop on Microbiome in HIV Pathogenesis, Prevention, and TreatmentScott Sherrill-Mix, Michelle Yang, Grace M Aldrovandi, et al.
Pageof 31